Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$19.15

0.15 (0.79%)

, AMGN

Amgen

$197.62

-0.36 (-0.18%)

07:30
08/07/18
08/07
07:30
08/07/18
07:30

Alder Biopharmaceuticals initiated with a Buy at Stifel

Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.

ALDR

Alder Biopharmaceuticals

$19.15

0.15 (0.79%)

AMGN

Amgen

$197.62

-0.36 (-0.18%)

NVS

Novartis

$83.49

0.17 (0.20%)

LLY

Eli Lilly

$102.00

1.4 (1.39%)

TEVA

Teva

$22.11

-0.065 (-0.29%)

  • 07

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 10

    Sep

  • 16

    Sep

ALDR Alder Biopharmaceuticals
$19.15

0.15 (0.79%)

06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/27/18
NEED
06/27/18
INITIATION
Target $28
NEED
Buy
Alder Biopharmaceuticals assumed with a Buy at Needham
Needham analyst Serge Belanger assumed Alder Biopharmaceuticals with a Buy rating and a price target of $28, saying the company is positioned as a "rare pure-play migraine story". Belanger cites the positive pivotal phase 3 trial data for its Eptinezumab drug where it met all the endpoints and demonstrated an efficacy profile relative to competitive treatments. The analyst believes that Eptinezumab will appeal to "most severe of migraine patients where it will generate blockbuster-level sales" of over $1B.
08/06/18
PIPR
08/06/18
INITIATION
Target $28
PIPR
Overweight
Alder Biopharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Alder Biopharmaceuticals with an Overweight rating and $28 price target. Alder is undervalued despite having a "late-stage, de-risked, and differentiated" asset that addresses the large, under-served migraine population, Brill tells investors in a research note. The analyst finds the stock "very attractive at current levels."
08/06/18
08/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Global Blood Therapeutics (GBT) initiated with an Overweight at Piper Jaffray. 2. Welltower (WELL) reinstated with a Neutral at Goldman Sachs. 3. Sage Therapeutics (SAGE) initiated with an Overweight at Piper Jaffray. 4. SoftBank (SFTBY) initiated with a Buy at UBS. 5. Alder Biopharmaceuticals (ALDR) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$197.62

-0.36 (-0.18%)

07/26/18
PIPR
07/26/18
NO CHANGE
Target $210
PIPR
Overweight
Amgen price target raised to $210 from $190 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target on Amgen to $210 and kept his Overweight rating after its Q2 earnings beat. The analyst cites upside contributions across the portfolio, with "impressive growth" from new products Repatha and Parsabiv and competitive position of key legacy products Neulasta and Enbrel. Raymond further states that in spite of the 12% year to date rise in the stock price, its valuation of 14.2-times expected 2018 earnings is in-line with the group.
07/30/18
PIPR
07/30/18
NO CHANGE
PIPR
Arrowhead pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he would remain a buyer of Arrowhead Pharmaceuticals shares ahead of a "busy" second half of the year. The company could have five RNAi candidates in the clinic this year, and partner Amgen (AMGN) nominated AMG-890 as a clinical candidate that could begin clinical trials this year. Tenthoff reiterated an Overweight rating and $17 price target on Arrowhead shares.
07/27/18
JEFF
07/27/18
NO CHANGE
Target $220
JEFF
Buy
Amgen price target raised to $220 from $200 at Jefferies
Jefferies analyst Michael Yee raised his price target for Amgen to $220 saying the company last night reported "another strong quarter." He thinks Amgen shares "will go well north" of $200-$220 if the company can manage Neulasta biosimilar risk and "take the fears off the table." Yee keeps a Buy rating on the stock.
07/27/18
RBCM
07/27/18
NO CHANGE
Target $193
RBCM
Sector Perform
Amgen price target raised to $193 from $183 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $193 after its revenue and earnings beat consensus in Q2, adding that the earnings call highlighted the company's "contracting competence offsetting competitive headwinds across multiple products". MacKay also keeps his Sector Perform rating on Amgen, noting that he has not seen a "significant inflection" in the company's growth products, with "price-for-volume contracting adding headwinds to these products' ability to fill in for base business erosion". The analyst adds that the patent cliffs for its key programs cannot be offset by Amgen's buybacks.
NVS Novartis
$83.49

0.17 (0.20%)

07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.
07/19/18
LEHM
07/19/18
UPGRADE
LEHM
Equal Weight
Novartis upgraded to Equal Weight from Underweight at Barclays
07/19/18
WELS
07/19/18
NO CHANGE
Target $240
WELS
Outperform
Allergan wet AMD data exceed 'unofficial benchmark,' says Wells Fargo
The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.
LLY Eli Lilly
$102.00

1.4 (1.39%)

07/25/18
07/25/18
DOWNGRADE
Target $99

Hold
Eli Lilly downgraded to Hold on valuation at Berenberg
As previously reported, Berenberg analyst Laura Sutcliffe downgraded Eli Lilly to Hold from Buy, stating that the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. While she thinks Lilly's premium to peers is deserved, Sutcliffe also sees the stock at a "reasonably full valuation" at current levels, she tells investors. She trimmed her price target on Lilly shares to $99 from $100.
07/25/18
CANT
07/25/18
NO CHANGE
Target $110
CANT
Overweight
Eli Lilly price target raised to $110 from $100 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen yesterday raised her price target for Eli Lilly to $110 citing the company's beat and raise quarter. The growth prospects for Lilly's key drugs - Trulicity, Jardiance, Taltz and Verzenio - as well as its pipeline assets, especially in pain, are underappreciated, Chen told investors in a post-earnings research note. She reiterates an Overweight rating on the shares.
07/25/18
BMOC
07/25/18
NO CHANGE
Target $90
BMOC
Market Perform
Eli Lilly price target raised to $90 from $80 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $90, saying the company is doing an "excellent" job in managing its mature franchises and should finish 2018 at the top end of its guidance. The analyst also believes that the company can achieve its 2015-20 annual revenue growth target of 5% or more. Arfaeil keeps his Market Perform rating however, noting that its valuation reflects the opportunities around Tanezumab, migraine and Alzheimer's franchises while also pointing to the "underappreciated" risks around its insulins franchise.
07/25/18
07/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spotify (SPOT) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak citing valuation. 2. Eli Lilly (LLY) downgraded to Hold from Buy at Berenberg with analyst Laura Sutcliffe saying the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. 3. Walmart (WMT) downgraded to Hold from Accumulate at Gordon Haskett with analyst Chuck Grom saying he thinks there are few near-term catalysts on the horizon and the margin outlook is not as transparent following a period of improvement and stabilization, and expects shares to be range bound for the balance of the year. 4. Hormel Foods (HRL) downgraded to Underperform from Neutral at Mizuho with analyst Jeremy Scott saying "volatile and retreating" pork margins bring rising risks to Hormel's earnings. 5. BJ's Wholesale (BJ) downgraded to Accumulate from Buy at Gordon Haskett with analyst Chuck Grom citing share strength following the IPO. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$22.11

-0.065 (-0.29%)

07/25/18
SBSH
07/25/18
NO CHANGE
SBSH
Buy
Citi opens 'catalyst watch' on Teva ahead of PDUFA date
Citi analyst Liav Abraham opened a "catalyst watch" on Teva Pharmaceutical ahead of the September 16 PDUFA date for fremanezumab for the prophylaxis of episodic and chronic migraine. The analyst has a Buy rating on the shares.
08/02/18
WELS
08/02/18
NO CHANGE
Target $23
WELS
Market Perform
Teva business remains challenged despite Q2 beat, says Wells Fargo
Wells Fargo analyst David Maris Teva delivered "what we had expected," namely a better than consensus Q2 fueled in large part by Copaxone not facing additional generics. However, despite the beat the overall business remains challenged, Maris tells investors. On the earnings call, Teva mentioned that they believe generic pricing the U.S. is improving, but Teva is not experiencing the benefit and expect that things will remain challenging, said Maris, who keeps a Market Perform rating and $23 price target on Teva shares.
08/02/18
WELS
08/02/18
NO CHANGE
WELS
Market Perform
Mylan may have negative read-through from Teva report, says Wells Fargo
Wells Fargo analyst David Maris highlighted some items in Teva's (TEVA) Q2 earnings report and conference call that he believes may have a negative read-through for Mylan (MYL). For one, Teva management said they expect the North American generics environment to remain challenging. Additionally, Copaxone sales were relatively flat sequentially, which would be a negative for Mylan if expectations are for increased contribution from Mylan's Copaxone generic in Q2. Mylan has a large pipeline of biosimilars and Teva mentioned it is building a facility for biosimilars in Germany, which indicates more competition, added Maris, who keeps a Market Perform rating on Mylan shares.
08/07/18
MZHO
08/07/18
NO CHANGE
Target $27
MZHO
Buy
Teva still confident in migraine drug approval, says Mizuho
Teva traded lower yesterday on news that Celltrion received a Form 483 related to an FDA inspection of its plant, Mizuho analyst Irina Koffler tells investors in a research note. The analyst says Teva management indicated to her that it had knowledge of 483 report at the time of its earnings call and still has confidence in approval of its migraine drug. Koffler keeps a Buy rating on Teva Pharmaceutical with a $27 price target.

TODAY'S FREE FLY STORIES

10:35
08/15/18
08/15
10:35
08/15/18
10:35
General news
Fed funds futures are rallying »

Fed funds futures are…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.80

-3 (-1.06%)

10:33
08/15/18
08/15
10:33
08/15/18
10:33
Technical Analysis
Technical Take: SPDR S&P 500 ETF breaks additional support »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.80

-3 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$113.29

0.19 (0.17%)

, MAR

Marriott

$119.80

-1.78 (-1.46%)

10:32
08/15/18
08/15
10:32
08/15/18
10:32
Hot Stocks
Marriott expands PepsiCo relationship with new multiyear deal »

PepsiCo (PEP) and…

PEP

PepsiCo

$113.29

0.19 (0.17%)

MAR

Marriott

$119.80

-1.78 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HMNY

Helios and Matheson

$0.04

-0.0135 (-27.00%)

10:32
08/15/18
08/15
10:32
08/15/18
10:32
Hot Stocks
Helios and Matheson: Creating a 'more sustainable path' for MoviePass »

"We far exceeded our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMNY

Helios and Matheson

$0.04

-0.0141 (-28.20%)

10:31
08/15/18
08/15
10:31
08/15/18
10:31
Hot Stocks
Helios and Matheson issues progress report on MoviePass »

Helios and Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:31
08/15/18
08/15
10:31
08/15/18
10:31
General news
Crude inventories for week of August 10 »

Crude oil inventories…

BSX

Boston Scientific

$34.05

0.36 (1.07%)

10:30
08/15/18
08/15
10:30
08/15/18
10:30
Options
Bullish option play in Boston Scientific as shares see relative strength »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 23

    Aug

10:30
08/15/18
08/15
10:30
08/15/18
10:30
General news
The 0.1% U.S. June business inventory rise »

The 0.1% U.S. June…

10:30
08/15/18
08/15
10:30
08/15/18
10:30
General news
U.S. VIX not dead yet, surging 20% »

U.S. VIX not dead yet,…

WEN

Wendy's

$17.71

-0.13 (-0.73%)

10:28
08/15/18
08/15
10:28
08/15/18
10:28
Conference/Events
Wendy's participates in a conference call with Stephens »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

CUR

Neuralstem

$1.19

(0.00%)

10:27
08/15/18
08/15
10:27
08/15/18
10:27
Earnings
Neuralstem reports Q2 EPS (4c) vs. (39c) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
08/15/18
08/15
10:25
08/15/18
10:25
Conference/Events
Vertical Group analyst to hold an analyst/industry conference call »

Metals/Mining &…

WMT

Walmart

$89.74

-1.065 (-1.17%)

, AMZN

Amazon.com

$1,892.64

-27.08 (-1.41%)

10:24
08/15/18
08/15
10:24
08/15/18
10:24
Earnings
On The Fly: What to watch in Wal-Mart earnings report »

WalMart (WMT) is…

WMT

Walmart

$89.74

-1.065 (-1.17%)

AMZN

Amazon.com

$1,892.64

-27.08 (-1.41%)

NFLX

Netflix

$328.11

-9.38 (-2.78%)

MSFT

Microsoft

$107.48

-1.67 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

EVBG

Everbridge

$54.40

-0.04 (-0.07%)

10:23
08/15/18
08/15
10:23
08/15/18
10:23
Conference/Events
Everbridge management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

NVDA

Nvidia

$258.69

-2.78 (-1.06%)

, WDC

Western Digital

$61.75

-3.23 (-4.97%)

10:22
08/15/18
08/15
10:22
08/15/18
10:22
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

NVDA

Nvidia

$258.69

-2.78 (-1.06%)

WDC

Western Digital

$61.75

-3.23 (-4.97%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GWPH

GW Pharmaceuticals

$132.44

-1.04 (-0.78%)

HAS

Hasbro

$97.55

-0.59 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WU

Western Union

$18.74

-0.075 (-0.40%)

10:20
08/15/18
08/15
10:20
08/15/18
10:20
Options
Put buyers in Western Union »

Put buyers in Western…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

M

Macy's

$37.10

-4.77 (-11.39%)

10:17
08/15/18
08/15
10:17
08/15/18
10:17
Hot Stocks
Macy's says SG&A dollars for the year expected to be higher than last year »

CFO Paula Price says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 17

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/15/18
08/15
10:17
08/15/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CISN

Cision

$16.33

0.07 (0.43%)

, OBSV

ObsEva

$13.25

0.27 (2.08%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CISN

Cision

$16.33

0.07 (0.43%)

OBSV

ObsEva

$13.25

0.27 (2.08%)

IDRA

Idera Pharmaceuticals

$9.06

0.545 (6.40%)

DTE

DTE Energy

$112.00

0.97 (0.87%)

TELL

Tellurian

$7.10

-0.01 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

NLSN

Nielsen

$25.50

-0.57 (-2.19%)

, UNP

Union Pacific

$148.61

-1.56 (-1.04%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NLSN

Nielsen

$25.50

-0.57 (-2.19%)

UNP

Union Pacific

$148.61

-1.56 (-1.04%)

KMB

Kimberly-Clark

$113.90

2.8 (2.52%)

WDC

Western Digital

$61.77

-3.21 (-4.94%)

TSRO

Tesaro

$27.70

-0.37 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 26

    Aug

  • 06

    Nov

NVDA

Nvidia

$259.49

-1.98 (-0.76%)

, HAS

Hasbro

$97.66

-0.48 (-0.49%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

NVDA

Nvidia

$259.49

-1.98 (-0.76%)

HAS

Hasbro

$97.66

-0.48 (-0.49%)

INCY

Incyte

$67.21

0.76 (1.14%)

NSC

Norfolk Southern

$171.79

-0.39 (-0.23%)

PZZA

Papa John's

$42.50

-0.5 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 26

    Aug

  • 06

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
08/15/18
08/15
10:16
08/15/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
U.S. NAHB housing market index fell 1 tick to 67 in August »

U.S. NAHB housing market…

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
Treasury Action: yields slumped back to lows »

Treasury Action: yields…

10:15
08/15/18
08/15
10:15
08/15/18
10:15
General news
Breaking General news story  »

Week of 8/10 EIA…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.